The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel
Authors:
- Brian W. OgilvieBOBrian W. Ogilvie
- Phyllis YerinoPYPhyllis Yerino
- Faraz KazmiFKFaraz Kazmi
- David B. BuckleyDBDavid B. Buckley
- Amin Rostami-HodjeganARAmin Rostami-Hodjegan
- Brandy L. ParisBPBrandy L. Paris
- Paul TorenPTPaul Toren
- Andrew ParkinsonAPAndrew Parkinson
- 1 November 2011
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 39 (11) , 2020-2033
Abstract
As a direct-acting inhibitor of CYP2C19 in vitro, lansoprazole is more potent than omeprazole and other proton pump inhibitors (PPIs), but lansoprazole does not cause clinically significant inhibition of CYP2C19 whereas omeprazole does. To investigate this apparent paradox, we evaluated omeprazole, esomeprazole, R-omeprazole, lansoprazole, and pantoprazole for their ability to function as direct-acting and metabolism-dependent inhibitors (MDIs) of CYP2C19 in pooled human liver microsomes (HLM) as well as in cryopreserved hepatocytes and recombinant CYP2C19. In HLM, all PPIs were found to be direct-acting inhibitors of CYP2C19 with IC(50) values varying from 1.2 μM [lansoprazole; maximum plasma concentration (C(max)) = 2.2 μM] to 93 μM (pantoprazole; C(max) = 6.5 μM). In addition, we identified omeprazole, esomeprazole, R-omeprazole, and omeprazole sulfone as MDIs of CYP2C19 (they caused IC(50) shifts after a 30-min preincubation with NADPH-fortified HLM of 4.2-, 10-, 2.5-, and 3.2-fold, respectively), whereas lansoprazole and pantoprazole were not MDIs (IC(50) shifts < 1.5-fold). The metabolism-dependent inhibition of CYP2C19 by omeprazole and esomeprazole was not reversed by ultracentrifugation, suggesting that the inhibition was irreversible (or quasi-irreversible), whereas ultracentrifugation largely reversed such effects of R-omeprazole. Under various conditions, omeprazole inactivated CYP2C19 with K(I) (inhibitor concentration that supports half the maximal rate of inactivation) values of 1.7 to 9.1 μM and k(inact) (maximal rate of enzyme inactivation) values of 0.041 to 0.046 min(-1). This study identified omeprazole, and esomeprazole, but not R-omeprazole, lansoprazole, or pantoprazole, as irreversible (or quasi-irreversible) MDIs of CYP2C19. These results have important implications for the mechanism of the clinical interaction reported between omeprazole and clopidogrel, as well as other CYP2C19 substrates.Keywords
This publication has 41 references indexed in Scilit:
- Clopidogrel–Drug InteractionsJACC, 2011
- Paraoxonase-1 is a major determinant of clopidogrel efficacyNature Medicine, 2010
- ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID UseJACC, 2010
- Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison StudiesClinical Pharmacology & Therapeutics, 2010
- Benzylic Oxidation of Gemfibrozil-1-O-β-Glucuronide by P450 2C8 Leads to Heme Alkylation and Irreversible InhibitionChemical Research in Toxicology, 2009
- Clopidogrel Inhibits CYP2C19‐Dependent Hydroxylation of Omeprazole Related to CYP2C19 Genetic PolymorphismsThe Journal of Clinical Pharmacology, 2009
- Stereoselective Disposition of Proton??Pump InhibitorsClinical Drug Investigation, 2008
- The Metabolism of Clopidogrel Is Catalyzed by Human Cytochrome P450 3A and Is Inhibited by AtorvastatinDrug Metabolism and Disposition, 2003
- Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans*Clinical Pharmacology & Therapeutics, 1999
- Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexesPharmacology & Therapeutics. Part A: Chemotherapy, Toxicology and Metabolic Inhibitors, 1977